TY - JOUR

T1 - Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing

AU - Lukyanov, Sergei A.

AU - Titov, Sergei E.

AU - Kozorezova, Evgeniya S.

AU - Demenkov, Pavel S.

AU - Veryaskina, Yulia A.

AU - Korotovskii, Denis V.

AU - Ilyina, Tatyana E.

AU - Vorobyev, Sergey L.

AU - Zhivotov, Vladimir A.

AU - Bondarev, Nikita S.

AU - Sleptsov, Ilya V.

AU - Sergiyko, Sergei V.

N1 - This research was funded by the Russian Science Foundation, grant number 20-14-00074-P.

PY - 2024/7

Y1 - 2024/7

N2 - Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, fibronectin 1 (FN1), and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes. A weak statistical correlation (0.0015 < p < 0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, FN1, and CDKN2A genes.

AB - Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, fibronectin 1 (FN1), and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes. A weak statistical correlation (0.0015 < p < 0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, FN1, and CDKN2A genes.

KW - CDKN2A

KW - FN1

KW - aggressive variants

KW - miRNA-146b

KW - miRNA-221

KW - papillary thyroid carcinoma

KW - recurrence risk

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85198452625&origin=inward&txGid=85759b37960caf5bb539fbc04d40600a

UR - https://www.mendeley.com/catalogue/f7ed0a71-32fb-3b07-958e-549430f764aa/

U2 - 10.3390/ijms25137090

DO - 10.3390/ijms25137090

M3 - Article

C2 - 39000197

VL - 25

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 13

M1 - 7090

ER -